The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol
Completed
Centocor Ortho Biotech Services, L.L.C.
Phase 4
2001-12-01
The purpose of the study was to evaluate the ability of a maintenance dosage regimen of
infliximab to achieve and sustain at least 40% improvement from baseline in the total joint
count in patients with active Rheumatoid Arthritis (RA) during methotrexate tapering.
Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)
Completed
Kansas Bioscience Authority
Phase 2
2011-09-01
The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat
patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or
prolymphocytic lymphoma (PLL).
Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)
Completed
The Leukemia and Lymphoma Society
Phase 2
2011-09-01
The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat
patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or
prolymphocytic lymphoma (PLL).
Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)
Completed
Therapeutics for Rare and Neglected Diseases (TRND)
Phase 2
2011-09-01
The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat
patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or
prolymphocytic lymphoma (PLL).
Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)
Completed
University of Kansas Medical Center
Phase 2
2011-09-01
The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat
patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or
prolymphocytic lymphoma (PLL).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
